Abbott Laboratories vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
7.1
Buy
Overall
7.1
Buy
Quality
Health
Growth
Valuation
Sentiment
ABT
Analysts see 31% upside to $118.64 consensus target.
⚠ earnings contracting 20% year-over-year.
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $118.64 (+30.8%)
25 analysts
BUY
Target $252.42 (+10.2%)
24 analysts
Fundamentals
ABT
JNJ
25.4×
Trailing P/E
26.5×
15.0×
Forward P/E
18.0×
13.9%
Profit Margin
21.8%
56.5%
Gross Margin
68.0%
—
ROE
26.4%
7.8%
Revenue Growth
9.9%
-19.7%
Earnings Growth
-52.9%
0.78
Beta
0.33
—
Price / Book
—
$157.6B
Market Cap
$551.5B
$90 – $139
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.